½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1368219

¼¼°èÀÇ ½ÉÀå ÀýÁ¦ ±â±â ½ÃÀå

Global Cardiac Ablation Devices Market

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 64 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Æı«ÀûÀÎ ±â¼úÀÌ Çõ½ÅÀ» ÃËÁø

½ÉÀå ºÎÁ¤¸ÆÀÇ Áõ°¡¿Í ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÉÀå ÀýÁ¦¼ú(CA) ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CA ½Ã¼ú°ú °ü·ÃµÈ À§ÇèÀÌ Àû±â ¶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ¼±È£µÇ°í ÀÖÀ¸¸ç, CA ½Ã¼ú¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ºñÀÀ±Þ(¼±ÅÃÀû) ÀÇ·á °³ÀÔÀÇ Á¦ÇÑÀ¸·Î ÀÎÇØ 2020³â°ú 2021³â¿¡ °¨¼ÒÇßÀ¸¸ç, 2022³âºÎÅÍ´Â ÆÒµ¥¹Í ±ÔÁ¦°¡ ¿ÏÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù, CA ½Ã¼úÀÇ ¼¼°è ¹é·Î±×°¡ CA ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇß½À´Ï´Ù. ½ÃÀå¿¡´Â CA ½Ã½ºÅÛ, Ä«Å×ÅÍ, ¹ßÀü±â ¹× ±âŸ Á¦Ç° ºÐ¾ß°¡ ÀÖ½À´Ï´Ù.

½ÉÀå ºÎÁ¤¸Æ Ä¡·á ½ÃÀå ÁøÀÔ ±â¾÷µéÀº ½ÉÀå ºÎÁ¤¸ÆÀ» ½Å¼ÓÇÏ°í Á¤È®ÇÏ°Ô Ä¡·áÇÏ´Â µ¿½Ã¿¡ ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ±â¼úÀûÀ¸·Î Áøº¸µÈ ¼Ö·ç¼Ç °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ½ÃÀÛÇß½À´Ï´Ù. ½ºÅ¸Æ®¾÷ ¹× ±â¼ú Á¦°ø¾÷ü¿ÍÀÇ Çù¾÷ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºÎÁ¤¸Æ Áø´ÜÀ» À§ÇÑ AI, ¼¾¼­ ±â¹Ý ¿þ¾î·¯ºí, Á¤È®µµ Çâ»óÀ» À§ÇÑ ·Îº¿ °øÇÐ, °í±Þ ¸ÅÇÎ ½Ã½ºÅÛ, À¯¿¬ÇÑ ¼¾¼­ Ĩ Ä«Å×ÅÍ µî Á¦Ç° Æ÷Æ®Æú¸®¿À¿¡ Æ÷ÇÔµÈ Ã·´Ü ±â¼ú ¹× ¼Ö·ç¼ÇÀÌ CA ±â±â ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù.

ÃÖ¼Òħ½ÀÀû ½ÉÀå ºÎÁ¤¸Æ Ä¡·á¿¡ ´ëÇÑ À¯¸®ÇÑ º¸Çè ¹× º¸Çè Á¤Ã¥ÀÇ °¡¿ë¼ºÀº CA ½Ã¼ú ½ÃÀåÀ» ´õ¿í µÞ¹ÞħÇÒ °ÍÀ¸·Î º¸À̸ç, CA ½Ã¼ú ±â¼ú¿¡¼­ RF ÀýÁ¦±â°¡ ¼¼°è CA ½ÃÀåÀÇ 65% ÀÌ»óÀ» Â÷ÁöÇÏ°í ÀÖÁö¸¸, ÃÖ¼Òħ½ÀÀû Á¢±Ù ¹æ½ÄÀ̶ó´Â ÀÌÀ¯·Î ³Ãµ¿ ÀýÁ¦ ÀåÄ¡ °¡ ºü¸£°Ô º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ³Ãµ¿ ÀýÁ¦ ±â¼úÀÇ ¹ßÀü°ú ½º¸¶Æ® ³Ãµ¿ ÀýÁ¦ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ Çõ½Å ±â¼úÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϸ鼭 ¿¹Ãø ±â°£ µ¿¾È Àü ¼¼°è ³Ãµ¿ ÀýÁ¦ Àåºñ ½ÃÀå ±Ô¸ð¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³Ãµ¿ ÀýÁ¦¼úÀº ¼±È£ÇÏ´Â CA ½Ã¼ú·Î ³Ãµ¿ ÀýÁ¦¼ú ±â¼úÀÇ Ã¤Åà Áõ°¡·Î À̾îÁö´Â ¸î °¡Áö ¹ßÀüÀÔ´Ï´Ù.

2022³â ¹Ì±¹¿¡¼­´Â Ä«Å×ÅÍ ±â¹Ý CA ½Ã¼úÀÇ ºóµµ°¡ ½ÉÀå À̽ÄÇü ÀüÀÚ±â±â ½Ã¼úÀÇ ºóµµ¸¦ ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÞµðÄɾ¼­ ½ÉÀå EP ½Ã¼úÀÇ ºñÀ²Àº Áö³­ 10³â°£ Å©°Ô Áõ°¡ÇßÀ¸¸ç, ÁÖ·Î Ä«Å×ÅÍ ±â¹Ý CA ½Ã¼úÀÌ ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ½É¹æ¼¼µ¿ Ä¡·á¸¦ À§ÇÑ ÆóÁ¤¸Æ °Ý¸®¸¦ À§ÇÑ ½ÉÀå Ä«Å×ÅÍ ±â¹Ý EP ½Ã¼úÀÇ ºñÀ²Àº Áö³­ ¸î ³â µ¿¾È ±ÞÁõÇß½À´Ï´Ù. °³½É¼ú°ú ÃÖ¼Ò Ä§½À ¼ö¼ú ¸ðµÎ¿¡¼­ »ç¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ºÎÁ¤¸Æ Ä¡·á¸¦ À§ÇÑ ³Ãµ¿ ÀýÁ¦¼úÀÇ º¸±ÞÀº ¿©·¯ »ç·Ê¿¡¼­ È¿°ú¿Í ¾ÈÀü¼ºÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº CA ½Ã¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ º¸»ó Á¤Ã¥°ú APACÀÇ ÀÇ·á °ü±¤ »ê¾÷ÀÇ ¼ºÀå¿¡ ÈûÀÔ¾î ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ³Ãµ¿ ÀýÁ¦¼ú°ú ¾à¹° ¿ä¹ý ¶Ç´Â RF ÀýÁ¦¼úÀ» °áÇÕÇÑ ÇÏÀ̺긮µå Á¢±Ù¹ý¿¡ »ç¿ëÇϱâ À§ÇÑ Ã·´Ü Àåºñ °³¹ßÀº ȯÀڵ鿡°Ô º¸´Ù ¾ÈÀüÇÏ°í °³ÀÎÈ­µÈ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

º» Á¶»ç º¸°í¼­´Â ¼¼°è ½ÉÀå ÀýÁ¦ ±â±â ½ÃÀåÀ» ºÐ¼®ÇÏ¿© ÃÖÁ¾»ç¿ëÀÚº°, ¿ëµµº°, ÀåÄ¡ À¯Çüº°, ½ÃÀå ±â¾÷º° ½ÃÀå Á¡À¯À² ºñÀ² µî Àüü ½ÃÀå Àü¸ÁÀ» ¼ö·ÏÇÏ°í ÀÖ½À´Ï´Ù. °Å½Ã°æÁ¦Àû ¿äÀÎ, ÃֽŠµ¿Çâ, ¼öÀÍ ¿¹Ãø, Â÷¼¼´ë CA ±â¼ú ¹× ÀåÄ¡, ¿©·¯ »ç·Ê ¿¬±¸¿Í ÇÔ²² °ËÅäÇÏ°í ÀÖ½À´Ï´Ù. Á¶»ç ±â°£Àº 2021³âºÎÅÍ 2027³â±îÁö, ¿¹Ãø ±â°£Àº 2023³âºÎÅÍ 2027³â±îÁöÀ̸ç, 2022³âÀ» ±âÁØ ¿¬µµ·Î »ï¾Ò½À´Ï´Ù. ÀÌ º¸°í¼­´Â Æı«Àû Çõ½Å, ¹Ì°³Ã´ ½Å±Ô ½ÃÀå, ½ÉÀå ºÎÁ¤¸Æ À¯º´·ü Áõ°¡ µî¿¡ ÃÊÁ¡À» ¸ÂÃç ±¸Ã¼ÀûÀÎ ½ÃÀå ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Àü·«Àû ¿øÄ¢

  • ¼ºÀåÀÌ ¾î·Á¿î ÀÌÀ¯
  • The Strategic Imperative 8(TM)
  • ½ÉÀå ÀýÁ¦ ±â±â ¼¼°è ½ÃÀå¿¡ ´ëÇÑ Àü·«Àû ¿øÄ¢ÀÇ ¿µÇâ
  • ¼ºÀå ±âȸ°¡ Growth Pipeline Engine(TM)

¼ºÀå ±âȸ ºÐ¼®

  • ½ÉÀå ÀýÁ¦ ±â±â ½ÃÀå
  • ½ÉÀå ÀýÁ¦ ±â±â ½ÃÀå : Á¦Ç° À¯Çüº° ¼¼ºÐÈ­
  • ½ÉÀå ÀýÁ¦ ±â±â ½ÃÀå : ½Ã¼úº° ¼¼ºÐÈ­
  • ÁÖ¿ä °æÀï»ç
  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹Ãø °¡Á¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø : Á¦Ç° ºÎ¹®º°
  • ¸ÅÃâ ¿¹Ãø : Áö¿ªº°
  • ¸ÅÃâ ¿¹Ãø ºÐ¼®
  • ¿¹Ãø ºÐ¼®
  • °æÀï ȯ°æ
  • CA ±â±â ½ÃÀå »óȲ : ±â¾÷º°
  • CA ±â±â ½ÃÀå »óȲ : ÃÖÁ¾»ç¿ëÀÚº°

CA ½Ã¼ú - ºñ±³ ºÐ¼®

  • ½ÉÀå ÀýÁ¦(CA)¶õ?
  • CA¿Í Ç׺ÎÁ¤¸ÆÁ¦(AAD)/½É¹æ¼¼µ¿ ¾à¹°¿ä¹ýÀÇ ºñ±³
  • Ä«Å×ÅÍ ÀýÁ¦¿Í ½ÉÀå ÆäÀ̽ÌÀÇ ºñ±³?

CA ½Ã¼ú - Áö¼Ó ÄÉ¾î ºÐ¼®

  • ½É¹æ¼¼µ¿ ½ºÅ©¸®´×ÀÇ ÁÖ¿ä Ãßõ»çÇ×
  • ½ÉÀå ÀýÁ¦ Ä¡·á - ½Ã¼ú
  • (Ä«Å×ÅÍ ±â¹Ý) CA°¡ ½Ã°£ÀÌ ¸¹ÀÌ °É¸®´Â ½Ã¼úÀÎ ÀÌÀ¯ - Áö¼Ó ÄÉ¾î ºÐ¼®
  • ½ÉÀå ÀýÁ¦ ½ÃÀå - ÁøÈ­ÇÏ´Â »ýÅ°è
  • »ç·Ê ¿¬±¸ 1 - ¹Ì±¹ÀÇ EP ½Ã¼ú µ¿Çâ(2013-2020³â)

½ÃÀå ±â¾÷°ú ¼Ö·ç¼Ç ¸®½ºÆ®

  • ±â¾÷°ú Á¦Ç° ¸®½ºÆ® - ½ÉÀå ÀýÁ¦ ¼Ö·ç¼Ç
  • ÁÖ¸ñÇÒ ¸¸ÇÑ ½ÉÀå ÀýÁ¦ ½Ã½ºÅÛ/¼Ö·ç¼Ç »óÀ§ Á¦Á¶¾÷ü

½ÉÀå ÀýÁ¦ Â÷¼¼´ë ±â¼ú°ú ¼Ö·ç¼Ç

  • »õ·Î¿î ½ÉÀå ÀýÁ¦ ±â¼ú°ú Å×Å©´Ð
  • Â÷¼¼´ë ºñ°¡¿­ ½ÉÀå ÀýÁ¦ ½Ã½ºÅÛ - Arga MedtechÀÇ Coherent Sine-Burst Electroporation(CSE) Pulsed Field Ablation(PFA)
  • Boston Scientific FARAPULSE(TM) PFA ½Ã½ºÅÛ
  • À¯¿¬ÇÑ Àü±Ø ÆÁ°ú Á¢ÃË·Â °¨Áö ±â´ÉÀÌ ÀÖ´Â ÀýÁ¦ Ä«Å×ÅÍ - AbbottÀÇ TactiFlex(TM)
  • ¿Âµµ ¸ð´ÏÅ͸µ ±â´ÉÀÌ °³¼±µÈ Ä«Å×ÅÍ - Johnson & Johnson(JnJ) (Biosense Webster)ÀÇ QDOT MICRO(TM) Ä«Å×ÅÍ
  • ÆÞ½º Çʵå ÀýÁ¦(PFA) - Â÷¼¼´ë ½ÉÀå ÀýÁ¦ ±â¼ú
  • ½ÃÀå ¸®´õ°¡ PFA ±â¼ú¿¡ ÅõÀÚÇÏ´Â ÀÌÀ¯ - MedtronicÀÇ PulseSelect PFA ½Ã½ºÅÛ ½ÃÇè »ç·Ê ¿¬±¸

¼ºÀå ±âȸ À¯´Ï¹ö½º

  • ¼ºÀå ±âȸ 1 : ÆÞ½º Çʵå ÀýÁ¦ÀÇ Â÷¼¼´ë ±â¼ú
  • ¼ºÀå ±âȸ 2 : ½ÉÀå ºÎÁ¤¸Æ Áø´ÜÀÇ ±â¼ú Áøº¸¿Í AI È°¿ë
  • ¼ºÀå ±âȸ 3 : Àü±â»ý¸®Çп¡¼­ ·Îº¸Æ½½ºÀÇ ¹Ì·¡
  • ¼ºÀå ±âȸ 4 : ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀÇ Å¸°Ù

´ÙÀ½ ½ºÅÜ

ksm 23.11.02

Disruptive Technologies Drive Innovation

Rising incidents of cardiac arrhythmia and the increasing demand for minimally invasive procedures boost the cardiac ablation (CA) market growth. In addition, fewer risks associated with the CA procedure make it a preference, worldwide. Global demand for CA procedures declined in 2020 and 2021 due to the COVID-19 pandemic restrictions on non-emergency (elective) medical interventions. With the lessening of pandemic restrictions from 2022, the worldwide backlog of CA procedures surged the CA device market growth. The market includes product segments of CA systems, catheters, generators, and others.

CA device market participants started investing heavily in technologically advanced solution development to treat cardiac arrhythmias quickly and precisely, with improved patient outcomes. With more collaborations with start-ups and technology providers, the CA device market is witnessing huge traction with advanced technologies and solutions in the product portfolio, such as AI in arrhythmia diagnosis, sensor-based wearables, robotics for enhanced precision, advanced mapping system, and flexible sensor-tip catheters.

The availability of favorable reimbursement and insurance policies for minimally invasive cardiac arrhythmia treatments will further support the market for CA procedures. In CA procedure technology, although RF ablators dominate the global CA market with more than 65% of the market share, cryoablation devices are rapidly gaining adoption due to their minimally invasive approach. Advancements in cryoablation technology and the growing demand for smart cryoablation devices are rapidly leading to the surge in the adoption of these innovative technologies and bolstering the global CA device market size in the forecast period. In APAC, balloon-based cryoablation and multi-electrode cryoablation are some advancements leading to increased adoption of cryoablation technology as a preferred CA procedure.

In 2022, the frequency of catheter-based CA procedures exceeded the number of cardiac implantable electronic device procedures in the US and is expected to surge during the forecast period. Rates of cardiac EP procedures in Medicare have increased considerably over the last decade, majorly driven by catheter-based CA procedures. The ratio of cardiac catheter-based EP procedures for pulmonary vein isolation for treating AFib has witnessed a rapid rise over the last few years. The prevalence of cryoablation for cardiac arrhythmia treatment, as it can be used in both open-heart and minimally invasive procedures, has proven effectiveness and safety in several cases. This growth is bolstered by favorable reimbursement policies for CA procedures and the growth of the medical tourism industry in APAC. Advanced device development for usage in a hybrid approach by combining cryoablation with drug therapy or RF ablation offers patients enhanced, personalized, and safer treatment options.

This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players. It examines macroeconomic factors, the latest trends, revenue forecasts, and next-generation CA technologies and devices, along with a few case studies. The study period is from 2021 to 2027, and the forecast period is from 2023 to 2027, with 2022 as the base year. The study provides specific market growth opportunities focusing on disruptive innovations, new unaddressed markets, increasing prevalence of cardiac arrhythmia, and others. The study concludes with the top 4 growth opportunities in the CA device market.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Cardiac Ablation Devices Market
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Cardiac Ablation Devices Market
  • Cardiac Ablation Devices Market Segmentation by Product Types
  • Cardiac Ablation Devices Market Segmentation by Procedures
  • Key Competitors
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast by Product Segments
  • Revenue Forecast by Region
  • Revenue Forecast Analysis
  • Forecast Analysis
  • Competitive Environment
  • Landscape of CA Devices Market by Players
  • CA Devices Market Landscape by End Users

CA Procedure-Comparative Analysis

  • What is Cardiac Ablation (CA)?
  • CA vs. Antiarrhythmic Drugs (AAD)/Medication for Atrial Fibrillation
  • Catheter Ablation vs. Cardiac Pacing?

CA Procedure-Care Continuum Analysis

  • Key Recommendations for AFib Screening
  • Cardiac Ablation Therapy-The Procedure
  • Why (catheter-based) CA Is a Time-consuming Procedure-Care Continuum Analysis
  • The Cardiac Ablation Market-An Evolving Ecosystem
  • Case Study 1-Trends in the US EP Procedures (2013-2020)

Market Players and Solutions List

  • List of Players and Products-Cardiac Ablation Solutions
  • Top Cardiac Ablation System/solution Manufacturers to Watch

Cardiac Ablation Next-generation Technologies and Solutions

  • New Cardiac Ablation Technologies and Techniques
  • Next-gen Non-thermal Cardiac Ablation System-Arga Medtech's Coherent Sine-Burst Electroporation (CSE) Pulsed Field Ablation (PFA)
  • Boston Scientific's FARAPULSE™ PFA System
  • Ablation Catheter with Flexible Electrode Tip and Contact Force Sensing-Abbott's TactiFlex™
  • Catheter with Improved Temperature Monitoring-Johnson & Johnson's (JnJ) (Biosense Webster) QDOT MICRO™ Catheter
  • Pulsed Field Ablation (PFA)-Next-gen Cardiac Ablation Technique
  • Why Market Leaders are Investing in PFA Technology-Medtronic PulseSelect PFA System Trial Case Study

Growth Opportunity Universe

  • Growth Opportunity 1: Next-gen Technology of Pulsed Field Ablation
  • Growth Opportunity 2: Technological Advancements and AI Use in Cardiac Arrhythmia Diagnosis
  • Growth Opportunity 3: Future of Robotics in Electrophysiology
  • Growth Opportunity 4: Target APAC Region

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦